Fusion pharmaceuticals strengthens actinium supply with onsite isotope production through expanded bwxt medical collaboration

Collaboration enables fusion to produce high purity actinium-225 at company's gmp manufacturing facility agreement furthers bwxt medical's position as a global leader in medical isotope supply hamilton, on and boston , nov. 16, 2023 /prnewswire/ -- fusion pharmaceuticals inc. (nasdaq: fusn), and bwxt medical ltd., a subsidiary of bwx technologies, inc. (nyse: bwxt), today announced that the companies have entered into a new agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.
BWXT Ratings Summary
BWXT Quant Ranking